DOD Biotech PCL (BKK:DOD)
Thailand · Delayed Price · Currency is THB 0.9800
-0.0100 (-1.01%)
Sep 3, 2026, 2:58 PM ICT
DOD Biotech PCL Income Statement
Financials in millions THB. Fiscal year is January - December.
Millions THB. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 529.06 | 608.98 | 645.38 | 663.61 | 537.16 | 1,015 |
Other Revenue | 14.01 | 12.23 | 16.65 | 29.09 | 11.17 | 3.03 |
| 543.07 | 621.21 | 662.04 | 692.71 | 548.33 | 1,018 | |
Revenue Growth | -17.99% | -6.17% | -4.43% | 26.33% | -46.16% | -5.70% |
Cost of Revenue | 366.07 | 398.92 | 438.58 | 406.36 | 396.66 | 580.7 |
Gross Profit | 177 | 222.3 | 223.46 | 286.35 | 151.68 | 437.65 |
Selling, General & Admin | 177.55 | 182.98 | 209 | 198.52 | 163.05 | 126.84 |
Operating Expenses | 177.55 | 182.98 | 209 | 198.52 | 163.05 | 128.35 |
Operating Income | -0.55 | 39.32 | 14.46 | 87.84 | -11.38 | 309.3 |
Interest Expense | -3.44 | -2.86 | -3.73 | -5.31 | -7.09 | -6.72 |
Interest & Investment Income | 1.57 | 2.01 | 0.73 | 0.25 | 0.11 | 0.25 |
EBT Excluding Unusual Items | -2.42 | 38.46 | 11.46 | 82.78 | -18.36 | 302.84 |
Gain (Loss) on Sale of Investments | -2.44 | 4.98 | 29.03 | 10.04 | -405.86 | 15.45 |
Asset Writedown | - | - | - | - | - | -53.23 |
Pretax Income | -4.86 | 43.45 | 40.49 | 92.82 | -424.23 | 265.06 |
Income Tax Expense | -9.66 | -6.65 | 13.32 | 28.3 | -79.11 | 31.96 |
Earnings From Continuing Operations | 4.8 | 50.1 | 27.17 | 64.51 | -345.12 | 233.1 |
Earnings From Discontinued Operations | -1.71 | 11.67 | -190.99 | -50.94 | -55.37 | -187.44 |
Net Income to Company | 3.09 | 61.77 | -163.82 | 13.57 | -400.49 | 45.66 |
Minority Interest in Earnings | -1.22 | -2.18 | 4.48 | -6.39 | 2.15 | 4.12 |
Net Income | 1.87 | 59.59 | -159.33 | 7.19 | -398.33 | 49.79 |
Net Income to Common | 1.87 | 59.59 | -159.33 | 7.19 | -398.33 | 49.79 |
Net Income Growth | -96.14% | - | - | - | - | -64.75% |
Shares Outstanding (Basic) | 453 | 450 | 450 | 435 | 410 | 410 |
Shares Outstanding (Diluted) | 453 | 450 | 450 | 435 | 410 | 410 |
Shares Change | 0.52% | - | 3.47% | 6.17% | - | - |
EPS (Basic) | 0.00 | 0.13 | -0.35 | 0.02 | -0.97 | 0.12 |
EPS (Diluted) | 0.00 | 0.13 | -0.35 | 0.02 | -0.97 | 0.12 |
EPS Growth | -96.16% | - | - | - | - | -64.45% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -104.64 | 42.43 | 12.31 | 4.72 | -194 | -37.93 |
Free Cash Flow Per Share | -0.23 | 0.09 | 0.03 | 0.01 | -0.47 | -0.09 |
Dividend Per Share | 0.050 | 0.050 | - | - | - | - |
Dividend Growth | - | - | - | - | - | - |
Gross Margin | 32.59% | 35.78% | 33.75% | 41.34% | 27.66% | 42.98% |
Operating Margin | -0.10% | 6.33% | 2.18% | 12.68% | -2.08% | 30.37% |
Profit Margin | 0.34% | 9.59% | -24.07% | 1.04% | -72.65% | 4.89% |
Free Cash Flow Margin | -19.27% | 6.83% | 1.86% | 0.68% | -35.38% | -3.72% |
EBITDA | 42.13 | 80.42 | 71.39 | 156.11 | 48.03 | 371.45 |
EBITDA Margin | 7.76% | 12.95% | 10.78% | 22.54% | 8.76% | 36.48% |
D&A For EBITDA | 42.68 | 41.1 | 56.93 | 68.27 | 59.41 | 62.15 |
EBIT | -0.55 | 39.32 | 14.46 | 87.84 | -11.38 | 309.3 |
EBIT Margin | -0.10% | 6.33% | 2.18% | 12.68% | -2.08% | 30.37% |
Effective Tax Rate | - | - | 32.89% | 30.49% | - | 12.06% |
Revenue as Reported | 543.07 | 621.21 | 662.04 | 692.71 | 548.33 | 1,018 |